What are the Challenges in Targeting IDH1 in Cancer Therapy?
Despite the advancements, targeting IDH1 mutations presents several challenges. One issue is the development of resistance to IDH1 inhibitors. Cancer cells can acquire secondary mutations that render these drugs less effective. Additionally, identifying patients who will benefit the most from IDH1-targeted therapies requires precise molecular diagnostics, which may not be available in all clinical settings.
